Intervention

Rituximab

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 87 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials87

Recruiting13

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

The CARDIOPROTECT TrialNCT07654426 · 2026-08-31

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyNCT07138898 · 2025-12-12

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaNCT06220032 · 2024-08-15

The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple SclerosisNCT06599307 · 2024-08-01

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.NCT06581562 · 2024-05-15

Belimumab After Rituximab in Resistant Primary Juvenile SSNCT06410833 · 2024-03-09

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid ArthritisNCT06003283 · 2024-01-09

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasNCT05389423 · 2023-06-27

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MSNCT05834855 · 2023-04-01

Autologous Stem Cell Transplantation in Patients With Systemic SclerosisNCT03630211 · 2018-07-31

Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureNCT03500731 · 2018-04-19

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)NCT01419561 · 2011-09-08

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseNCT03414502 · 2007-12-10

AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")NCT07649304 · 2026-10-09

NOT_YET_RECRUITING

Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid ArthritisNCT06175338 · 2023-06-14

Anti-CD20 Antibodies for Treatment of SLE-PAHNCT05828147 · 2023-05-25

A Randomized Controlled Trial With Rituximab for Psychotic Disorder in AdultsNCT05622201 · 2023-03-21

ACTIVE_NOT_RECRUITING

Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System InvolvementNCT04323566 · 2022-05-01

ENROLLING_BY_INVITATION

Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in MalawiNCT04585893 · 2021-06-22

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple SclerosisNCT04688788 · 2021-04-28

ACTIVE_NOT_RECRUITING

Safety of HMA-CD20 in Patients With HFrEFNCT03332888 · 2021-01-01

Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple SclerosisNCT05078177 · 2020-12-21

Safety and Efficacy of Cladribine Therapy After Anti CD20 TherapyNCT04640818 · 2020-12-17

Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS DiseaseNCT04578639 · 2020-11-02

ACTIVE_NOT_RECRUITING

Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot TrialNCT04507477 · 2020-07-07

Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)NCT04121403 · 2019-10-16

Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)NCT03983018 · 2019-08-07

RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MSNCT03979456 · 2018-07-04

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerNCT03432741 · 2018-03-27

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasNCT03220022 · 2018-03-16

ACTIVE_NOT_RECRUITING

Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.NCT03164473 · 2018-03-07

Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsNCT03315923 · 2017-12-01

IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2NCT03194815 · 2017-11-01

ACTIVE_NOT_RECRUITING

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaNCT03096782 · 2017-10-13

COMparison Between All immunoTherapies for Multiple Sclerosis.NCT03193866 · 2017-06-02

Safety of Switching From Rituximab to Ocrelizumab in MS PatientsNCT02980042 · 2017-01-01

RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.NCT02746744 · 2016-05-01

Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's SyndromeNCT02631538 · 2016-02-17

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin LymphomaNCT02337985 · 2015-11-20

ACTIVE_NOT_RECRUITING

Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)NCT02304354 · 2015-03-09

A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis PatientsNCT02253264 · 2014-11-01

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLNCT01994382 · 2013-08-30

MabionCD20® Compared to MabThera® in Patients With Rheumatoid ArthritisNCT02468791 · 2013-05-01

Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid ArthritisNCT01759030 · 2012-12-01

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesNCT01471067 · 2012-07-13

An Observational Study of MabThera in Participants With Severe Active Rheumatoid ArthritisNCT01613027 · 2012-02-01

Comparison of Rituximab Induction Therapy Followed by Glatiramer AcetateNCT01569451 · 2012-02-01

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha TherapyNCT01592292 · 2011-11-01

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) AgentNCT01641952 · 2011-10-01

Study in Patients With Primary Breast Diffuse Large B-cell LymphomaNCT01448096 · 2011-08-01

SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.NCT01295151 · 2011-08-01

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)NCT01086540 · 2011-06-24

Study of Sonographic Efficacy of Rituximab in Rheumatoid ArthritisNCT01765374 · 2011-02-01

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell LymphomasNCT01193842 · 2010-10-06

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)NCT01212094 · 2010-09-01

Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid ArthritisNCT01244958 · 2010-08-01

Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid ArthritisNCT01593332 · 2010-07-01

Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic TherapyNCT01021735 · 2010-04-01

Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)NCT02731560 · 2010-01-01

An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid ArthritisNCT01071798 · 2010-01-01

Common conditions

Leading sponsors

National Cancer Institute (NCI) 10 Hoffmann-La Roche 9 Genentech, Inc. 4 National Institute of Allergy and Infectious Diseases (NIAID) 4 Anders Svenningsson 2 Karolinska Institutet 2 M.D. Anderson Cancer Center 2 Paul Szabolcs 2 Region Örebro County 2 University of Colorado, Denver 2 Alexion Pharmaceuticals, Inc. 1 Amsterdam UMC, location VUmc 1 Assistance Publique - Hôpitaux de Paris 1 Beth Israel Deaconess Medical Center 1 Biocad 1

Trial status mix

COMPLETED52

RECRUITING13

ACTIVE_NOT_RECRUITING7

UNKNOWN7

TERMINATED6

ENROLLING_BY_INVITATION1

NOT_YET_RECRUITING1

Phase mix

PHASE240

PHASE319

PHASE118

PHASE48

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.